Nephrocare Health Services Ltd Q1 FY27 Earnings Analysis

- Revenue for FY '26 grew by 32.2% YoY to INR 998.8 crores, driven by higher treatment volumes, improved clinic utilization, and increased revenue per treatment with strong international market contribution. - Treatment volume increased by 16.6% to 3,844,658 sessions in FY '26, supported by network expansion and better utilization. - Active guest count grew 11.8% to nearly 37,000 patients. - Clinic additions planned: 40-50 new clinics in India and 12-15 in the Philippines annually, supporting steady growth in treatment volumes. - No large price increases expected next year; revenue per treatment growth will mainly come from geographic mix (higher contribution from international markets). - New geographies, large acquisitions, and PPP projects remain growth levers but are unpredictable and in investment phase (e.g., Saudi Arabia). - Overall, steady growth in sales/revenue and treatment volume is expected through network expansion and improved utilization.

- Nephrocare Health Services projects a medium-term CAGR growth of 15% to 20% over the next 3-4 years driven by three key growth levers: same-clinic growth, new clinic rollouts in existing geographies, and expansions into new geographies or acquisitions. - FY '26 EBITDA grew 37.6% to INR 238.1 crores, with margin expansion of 100 bps to 23.8%; adjusted PAT grew 74.6% to INR 128.3 crores with PAT margin improving by 310 bps to 12.8%. - Operating cash flow remained strong at INR 233 crores; despite higher capital allocation (INR 165 crores), free cash flow was positive at INR 68 crores. - Earnings growth is expected to continue as the company scales up treatment volumes, improves utilization, benefits from higher-margin international mix, and exercises disciplined capital allocation. - Price increases are lumpy and infrequent; earnings growth will primarily come from volume and network expansions rather than price hikes. - Overall, sustained volume growth, platform scalability, and margin improvement underpin confident profit and EPS growth expectations.

- FY 2026 capex was INR 165 crores, split between India, Philippines, and Uzbekistan. - Capex per bed: India ~INR 10-11 lakhs (payback 3.5-4 years), Philippines ~INR 40-45 lakhs (payback ~1-1.5 years), Uzbekistan ~INR 18-20 lakhs (payback ~1-1.5 years). - Planned clinic additions: 40-50 in India and 12-15 in the Philippines annually, excluding any large PPP contracts or acquisitions. - No large price increases expected in the coming year; capex includes investments in IT, supply chain, business development, and international expansion. - NephroPlus is exploring PPP models, Greenfield clinics, and acquisitions, especially in the Philippines to capture the long tail of 600+ clinics. - Saudi Arabia business is in the investment phase with recent tenders and plans to open the first clinic shortly. - Continued strategic investments in talent acquisition, training academies (Enpidia), and geographic expansion in dialysis and CKD management.

The provided pages of the document do not mention any current or planned fundraising activities through debt or equity. Specifically: - There is no information on debt or equity fundraising plans mentioned. - The discussion focuses primarily on clinic expansions, acquisitions, operational metrics, and financial performance. - Investment phases in new geographies like Saudi Arabia are mentioned but there is no indication of fundraising to support these. - Capex and expenditure details are discussed but are not linked to any fundraising activities. - The company appears to be funding expansions through operational cash flow and investments without reference to external capital raising. Therefore, based on the available pages (up to page 24), no details on current or future fundraising through debt or equity are disclosed.

- There is no explicit mention of a "current order book" or "pending orders" in the provided excerpts. - In Saudi Arabia, a new tender was released recently (around a month ago) and is currently at the Expression of Interest (EOI) stage; further clarity on order size and contracts will be available in a few quarters. - The PPP contract in Uttarakhand is under renewal/tendering stage, expected to conclude in 2-4 months, subject to government timelines. - Growth plans include 40-50 new clinics in India and 12-15 in the Philippines for the coming year, excluding any large PPP or acquisitions. - Large M&A, PPPs, or new geography expansions are considered "step events" and are unpredictable, not factored into existing forecasts/order books. - The Saudi Arabia business remains in the investment phase with tenders underway but no confirmed orders yet.